Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
May 01, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Open market or private sale of non-derivative or derivative security	20,120	$134.54	845,986
May 01, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Open market or private sale of non-derivative or derivative security	12,945	$135.29	833,041
Mar 27, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Other acquisition or disposition	--	--	5,534
Mar 26, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Open market or private sale of non-derivative or derivative security	32,140	$120.21	867,216
Mar 26, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Open market or private sale of non-derivative or derivative security	1,010	$121.09	866,206
Feb 16, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Other acquisition or disposition	--	--	5,534
Feb 15, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	129,902	$8.50	962,943
Feb 15, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	10,103	$109.29	952,840
Feb 15, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	55,191	$109.29	897,649
Feb 15, 2012	YANCOPOULOS GEORGE Director, EVP CSO President Regeneron Re	Director, EVP CSO President Regeneron Re	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	3,430	$8.50	901,079

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media